The Center for Biological Sequence Analysis at the Technical University of Denmark (DTU) in Lyngby, Denmark conducts basic and applied research in biology and medicine using the tools of bioinformatics and systems biology. Since its formation in 1993, the center has grown into eleven specialized research groups, with the majority of the research focused on human health. The center is equipped with a substantial supercomputing and data warehousing infrastructure and is currently one of the largest academic research groups within bioinformatics and systems biology in Europe. The staff of over 90 multi-disciplinary scientists includes molecular biologists, biochemists, medical doctors, physicists and computer

The Cancer Research UK London Research Institute (LRI) in London, UK is a core-funded institute of Europe’s largest cancer charity, Cancer Research UK.  It employs more than 550 scientific staff and PhD students and is dedicated to innovative research to improve the understanding and treatment of cancer. It has an outstanding international reputation for its research in the biology of cancer and provides first class central research support facilities including a robotic high throughput screening laboratory, state of the art bioinformatics facilities and next generation DNA sequencing facilities.

The Wellcome Trust Sanger Institute (WTSI) in Hinxton, Cambridge, UK  is a not-for-profit research institute funded by the Wellcome Trust and known primarily for its work in the sequencing and functional analysis of genomes. The Institute’s work underpins biological and medical research worldwide through large-scale analysis, focused research and collaborations. In the Cancer Genome Project, Institute researchers have pioneered the application of systematic genome-wide analyses to the somatic genetics of cancer and have led in the development of high-throughput approaches to identifying somatic variants in cancer. Scientists in the Cancer Genome Project have used new sequencing technologies extensively in the annotation of cancer genomes through identification of point mutations, copy number changes and rearrangements.

The Royal Marsden Hospital (RMH) in London, UK was the first hospital in the world dedicated to research into cancer and to cancer treatment. Today the hospital with its academic partner, The Institute of Cancer Research, forms the largest comprehensive cancer centre in Europe with over 40,000 patients seen each year. In the Healthcare Commission’s ‘Annual Health Check’ in October 2009, The RMH was the only NHS trust in the country to be awarded the highest rating in the national performance rankings for 4 years in a row. The Royal Marsden is world-renowned for the quality of its educational programs and more specialist oncology nurses and doctors are trained at RMH than anywhere else in the UK.

Institut Gustave Roussy in Villejuif, France is a cancer centre with 2500 staff located in Villejuif, south of Paris, France. In the 400-bed hospital with its 124 statutory physicians, annually over 11,000 new patients are recruited, 130,000 patients attend its clinics and 42,000 patients receive treatment. Research is conducted by 400 research scientists under the oversight of a scientific council, a therapeutic trials commission and a clinical research committee.

The Semmelweis University in Budapest, Hungary ranks among the most prestigious Hungarian research institutions where 1172 staff members in approximately 80 departments are involved in R&D activities. The university also houses a significant amount of high-end technology and aims to establish itself as an emerging central research and knowledge centre in Hungary. The Semmelweis team has a particular focus on the research of individualized cancer treatments, and on the translation of genomic measurements results obtained in cell culture models for prediction of cancer therapy response.

The Natural and Medical Sciences Institute (NMI) at the University of Tübingen in Reutlingen, Germany, a non-profit, private foundation, is an application-oriented research institute that makes the results of scientific study available to industry. The interdisciplinary approach of the NMI includes basic research as well as practical problem solving in the form of applied research and development, consultancy, testing, measuring and analysis, scientific studies, and implementation in the fields of pharma- and biotechnology, biomedical technology as well as surface and interface technologies. The NMI makes use of interdisciplinary know-how, modern equipment, quality management processes and a network of companies including various branches of industry, in particular the life sciences.

The European Hospital Georges Pompidou (HEGP) in Paris, France is an 800-bed university hospital located in Paris, France with two main departments: a cardiovascular department “Pôle cardiovasculaire” and an oncology department “Pôle cancérologie”. The “Pôle cancérologie” employs 181 physicians and annually recruits over 6,800 new patients. Annually, 8,500 patients are admitted to the ward and 35,000 patients attend the outpatient clinic. Research is conducted mainly in cardiovascular diseases and in oncology.

Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO) in Berlin, Germany is a small enterprise that has broad expertise in preclinical pharmacology, pharmacokinetics, and toxicology for the characterization of novel anticancer therapeutics and diagnostics like: cytostatics, biologicals (peptides, antibodies), (anti)-hormones, immunomodulators (cytokines), and gene therapeutics. EPO answers questions concerning mechanisms of tumour growth and metastasis, side effects of drugs, drug resistance, alternative formulations (liposomes, nanoparticles), pharmacokinetics/biodistribution, tumorigenicity of genetically engineered cells, engraftment of human hematopoietic progenitors, and detection of occult tumour cells. EPO has research laboratories based on the Biomedical Research Campus Berlin-Buch, with an expanding research group comprising 25 staff currently.

Horizon Discovery Ltd in Cambridge, UK is a translational genomics and personalised medicine company founded in June 2007; headquartered at IQ Cambridge, Cambridge, UK and with additional research laboratories in Torino, Italy. Horizon’s goal is to convert new information on the genetic causes of cancer into gold-standard laboratory models that will facilitate the discovery of drugs that target these defects. Central to this aim is Horizon Discovery’s gene-targeting technology ‘GENESIS’, which enables for the first time any endogenous gene in a human cell to be routinely and precisely altered. Using this technology, Horizon creates genetically-defined and accurate human disease models that represent specific cancer patient populations and their matched normal genetic backgrounds.

Bayer Schering Pharma AG (BSP) in Berlin, Germany is a specialized pharmaceutical company focusing research and business activities on therapy areas with high medical need such as diagnostic imaging and oncology. BSP employs more than 40,000 people and markets its products in over 100 countries. BSP has a long standing expertise and track record in the development of anti-angiogenic drugs as well as biomarker research. Research programs and activities are consolidated in Berlin and Wuppertal, and both locations have the technologies for target discovery, lead generation and optimization, drug metabolism and pharmacokinetics, as well as toxicology and clinical pharmacology.

Leave a Comment

No Comments Yet!